Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 149

Sort by

Sort Order Select

Journal Articles

Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry

Blood (2024) 143 (14): 1365–1378.

https://doi.org/10.1182/blood.2023023142

Published: 2024

Includes: Supplemental data

Journal Articles

Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Blood (2023) 142 (Supplement 1): 619.

https://doi.org/10.1182/blood-2023-173225

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Systemic Mastocytosis

Blood (2023) 142 (Supplement 1): 3605.

https://doi.org/10.1182/blood-2023-178304

Published: 2023

Journal Articles

ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Andreas Hochhaus, Jorge Cortes, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Susanne Saussele, Francois Mahon, Tim H. Brümmendorf, Shruti Kapoor, Tracey McCulloch, Peter Schuld, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 6388.

https://doi.org/10.1182/blood-2023-186773

Published: 2023

Journal Articles

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Blood (2023) 142 (Supplement 1): 721.

https://doi.org/10.1182/blood-2023-186160

Published: 2023

Journal Articles

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Blood (2023) 142 (Supplement 1): 446.

https://doi.org/10.1182/blood-2023-182792

Published: 2023

Journal Articles

Analysis of the Impact of Body Mass Index (BMI) on the Durability of Response in Patients with Aplastic Anemia Treated with Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG)

Jeanette Walter, Benjamin Rolles, Yannic Schumacher, Frauke Theis, Leo Hansmann, Daniel Heudobler, Markus Radsak, Michael Heuser, Julia-Annabell Georgi, Jörg Chromik, Beatrice Drexler, Jörg Schubert, Kim Kricheldorf, Susanne Isfort, Jens Panse, Tim H. Brümmendorf, Fabian Beier

Blood (2023) 142 (Supplement 1): 5641.

https://doi.org/10.1182/blood-2023-183075

Published: 2023

Journal Articles

Real-Life Data of Cyclosporine (CsA) Tapering in Patients with Very/ Severe Aplastic Anemia (v/sAA) Treated with Horse Anti-Thymocyte Globulin (hATG/CsA) Suggest Higher Risk of AA Relapse at Cyclosporine Plasma Levels below 100 Nanogram per Milliliter

Jeanette Walter, Kim Kricheldorf, Yannic Schumacher, Susanne Isfort, Jörg Chromik, Beatrice Drexler, Frauke Theis, Jens Panse, Tim H. Brümmendorf, Fabian Beier

Blood (2023) 142 (Supplement 1): 5636.

https://doi.org/10.1182/blood-2023-183046

Published: 2023

Journal Articles

Inter-Facility Evaluation of Machine Learning Based Deep Hematopoietic Cell Classifiers for Cytological Evaluation of Hematopoiesis

Julian Thull, Martina Crysandt, Barbara Klinkhammer, Peter Boor, Tim H. Brümmendorf, Volkmar Schulz, Barbara Klinkhammer, Dorit Merhof, Edgar Jost

Blood (2023) 142 (Supplement 1): 5036.

https://doi.org/10.1182/blood-2023-184399

Published: 2023

Journal Articles

Interferon-Alpha Impairs Neoplastic Vasculogenesis in a 3D iPSC-Based Model of JAK2V617F+ Myeloproliferative Neoplasms

Madeline J. Caduc, Martin Grasshoff, Sabrina Ernst, Gerhard Müller-Newen, Jörg Eschweiler, Ivan G. Costa, Tim H. Brümmendorf, Steffen Koschmieder, Marcelo Szymanski de Toledo

Blood (2023) 142 (Supplement 1): 742.

https://doi.org/10.1182/blood-2023-180977

Published: 2023

Journal Articles

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Blood (2023) 142 (Supplement 1): 4539.

https://doi.org/10.1182/blood-2023-180730

Published: 2023

Journal Articles

Quality of Life Analysis in Patients with AA Using the QLQ-AA/PNH-54 at Initial Diagnosis of AA - a Registry Based Analysis

Jeanette Walter, Andrea Petermann-Meyer, Hatice Soysal, Anna Doleschall, Deborah Christen, Kim Kricheldorf, Susanne Isfort, Tim H. Brümmendorf, Fabian Beier, Jens Panse

Blood (2023) 142 (Supplement 1): 5635.

https://doi.org/10.1182/blood-2023-182810

Published: 2023

Journal Articles

ABL001 (asciminib) Efficiently Targets Transplantable BCR::ABL1 Lymphoid Blast Crisis in the Scl-Tta-p210-BCR::ABL1 Mouse Model

Nicolas Chatain, Julian Baumeister, Marcelo Szymanski de Toledo, Dickson W.L. Wong, Siddharth Gupta, Kristina Pannen, Bärbel Junge, Tim H. Brümmendorf, Peter Boor, Steffen Koschmieder

Blood (2023) 142 (Supplement 1): 4193.

https://doi.org/10.1182/blood-2023-179809

Published: 2023

Journal Articles

Germline Variants in MDM4 Cause a Disorder of p53 Dysregulation and Insufficient Telomere Maintenance

Robert Meyer, Matthias Begemann, Marcus Jakob, Claudia Khurana, Daniela Dey, Tarek Hanafee Alali, Heinz Gabriel, Kim Kricheldorf, Margherita Vieri, Susanne Isfort, Martin Kirschner, Jens Panse, Udo Kontny, Selim Corbacioglu, Tim H. Brümmendorf, Ingo Kurth, Fabian Beier

Blood (2022) 140 (Supplement 1): 2951–2952.

https://doi.org/10.1182/blood-2022-168631

Published: 2022

Journal Articles

Efficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia

Michael W. Deininger, Tim H Brummendorf, Jeffrey H. Lipton, Dragana Milojkovic, Leif Stenke, Eric Leip, Simon Purcell, Andrea Viqueira, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 3913–3915.

https://doi.org/10.1182/blood-2022-163276

Published: 2022

Journal Articles

Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome

Blood (2022) 140 (Supplement 1): 6262–6264.

https://doi.org/10.1182/blood-2022-164702

Published: 2022

Journal Articles

Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 287–288.

https://doi.org/10.1182/blood-2022-159357

Published: 2022

Journal Articles

ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase

Andreas Hochhaus, Susanne Saussele, Francois-Xavier Mahon, Virginia Pilipovic, Yifan Zhang, Peter Schuld, Tim H. Brümmendorf

Blood (2022) 140 (Supplement 1): 6787–6788.

https://doi.org/10.1182/blood-2022-163051

Published: 2022

Journal Articles

Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent Kinase-9 (CDK9) Inhibitor AZD4573 in Relapsed/Refractory Hematological Malignancies: A Phase 1 First-in-Human Study

Tim H. Brummendorf, Patrick Medd, Raphael Koch, Stephan Stilgenbauer, Shringi Sharma, Yun He, Stefanie Meyer, Margaret C. Wey, Jamal Saeh, Richard F. Olsson, Arnon P. Kater

Blood (2022) 140 (Supplement 1): 3126–3127.

https://doi.org/10.1182/blood-2022-167203

Published: 2022

Journal Articles

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Blood (2022) 140 (Supplement 1): 1790–1793.

https://doi.org/10.1182/blood-2022-157265

Published: 2022

NARROW

Virus-reactive T cells expanded in aplastic anemia eliminate hematopoietic progenitor cells by molecular mimicry

Firstline Treatment with Ruxolitinib Versus Best Available Therapy in Patients with Polycythemia Vera: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Systemic Mastocytosis

ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1 -Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Analysis of the Impact of Body Mass Index (BMI) on the Durability of Response in Patients with Aplastic Anemia Treated with Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG)

Real-Life Data of Cyclosporine (CsA) Tapering in Patients with Very/ Severe Aplastic Anemia (v/sAA) Treated with Horse Anti-Thymocyte Globulin (hATG/CsA) Suggest Higher Risk of AA Relapse at Cyclosporine Plasma Levels below 100 Nanogram per Milliliter

Inter-Facility Evaluation of Machine Learning Based Deep Hematopoietic Cell Classifiers for Cytological Evaluation of Hematopoiesis

Interferon-Alpha Impairs Neoplastic Vasculogenesis in a 3D iPSC-Based Model of JAK2V617F+ Myeloproliferative Neoplasms

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Quality of Life Analysis in Patients with AA Using the QLQ-AA/PNH-54 at Initial Diagnosis of AA - a Registry Based Analysis

ABL001 (asciminib) Efficiently Targets Transplantable BCR::ABL1 Lymphoid Blast Crisis in the Scl-Tta-p210-BCR::ABL1 Mouse Model

Germline Variants in MDM4 Cause a Disorder of p53 Dysregulation and Insufficient Telomere Maintenance

Efficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia

Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome

ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase

Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent Kinase-9 (CDK9) Inhibitor AZD4573 in Relapsed/Refractory Hematological Malignancies: A Phase 1 First-in-Human Study

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only